|1.||Shen, Yi: 2 articles (04/2012 - 03/2012)|
|2.||Kuwada, Scott K: 2 articles (04/2012 - 03/2012)|
|3.||Cory, Ann H: 2 articles (03/2007 - 01/2005)|
|4.||Cory, Joseph G: 2 articles (03/2007 - 01/2005)|
|5.||Mabuchi, Seiji: 2 articles (11/2004 - 05/2004)|
|6.||Kimura, Akiko: 2 articles (11/2004 - 05/2004)|
|7.||Takahashi, Kazuhiro: 2 articles (11/2004 - 05/2004)|
|8.||Ohmichi, Masahide: 2 articles (11/2004 - 05/2004)|
|9.||Nishio, Yukihiro: 2 articles (11/2004 - 05/2004)|
|10.||Murata, Yuji: 2 articles (11/2004 - 05/2004)|
11/15/2004 - "Moreover, treatment with BAY 11-7085 increased the efficacy of paclitaxel-induced inhibition of intraabdominal dissemination and production of ascites in athymic nude mice inoculated intraperitoneally with Caov-3 cells. "
05/28/2004 - "Moreover, treatment with BAY 11-7085 increased the efficacy of the cisplatin-induced inhibition of the intra-abdominal dissemination and production of ascites using athymic nude mice inoculated intraperitoneally with Caov-3 cells. "
11/01/2003 - "Delayed administration of alpha-melanocyte-stimulating hormone or combined therapy with BAY 11-7085 protects against gut ischemia-reperfusion injury."
04/01/2003 - "BAY 11-7085 inhibited the former, but not the latter, phosphorylation pathway, whereas alpha-melanocyte-stimulating hormone, which is effective in limiting late ischemia-reperfusion injury to the intestine, inhibited tyrosine phosphorylation of IkappaB-alpha. "
04/01/2012 - "Treatment with BAY 11-7085 restored juxtacrine death receptor signaling during the adhesion of the cancer cells to mesothelial cells, which line the peritoneum. "
12/15/2007 - "In vivo, the effects of BAY 11-7085 on the growth of human RCC tumors were investigated in nude mice. "
09/22/2015 - "Our results demonstrate that the combination of BZ and the IKK inhibitor Bay 117085 significantly reduces the growth of ovarian tumor xenografts in nude mice when compared to either drug alone. "
09/22/2015 - "Mice treated with the BZ/Bay 117085 combination exhibit smallest tumors, and lowest levels of IL-8. "
03/01/2007 - "Since parthenolide, BAY 11-7085 and fenretinide are well known drugs in clinical trials, an understanding of the nature of the interactions between or among the apoptotic pathways could lead to the design of better clinical protocols using these drugs that will promote apoptosis in tumor cells."
07/01/2007 - "Application of the nuclear factor-kappaB inhibitor BAY 11-7085 for the treatment of endometriosis: an in vitro study."
07/01/2007 - "Therefore, BAY 11-7085 could be used as a therapeutic agent for the treatment of endometriosis."
01/01/2008 - "Two NF-kappaB inhibitors (BAY 11-7085 and SN-50) were injected intraperitoneally on days 0, 2 and 4 after endometriosis induction, and endometriotic lesions were recovered on day 5. Number, mass, fluorimetry and surface (morphometry) of endometriotic lesions were quantified. "
07/01/2007 - "To examine the potential application of BAY 11-7085 in the treatment of endometriosis, we investigated the effects of this agent on the cell proliferation and apoptosis of cultured ovarian endometriotic cyst stromal cells (ECSCs) by a modified methylthiazole tetrazolium assay, a 5-bromo-2'-deoxyuridine incorporation assay, and internucleosomal DNA fragmentation assays. "
|5.||Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis)
11/01/2000 - "This study assessed the effects of 2 different inhibitors of NF-kappaB activation on central nervous system complications and clinical symptoms in an advanced stage of experimental pneumococcal meningitis: the calpain inhibitor I N-acetyl-leucinyl-leucinyl-norleucinal (ALLN), which interferes with IkappaB proteolysis, and BAY 11-7085, which inhibits IkappaB phosphorylation. "
|2.||NF-kappaB inhibitor alpha
|6.||NF-kappa B (NF-kB)
|1.||Heterologous Transplantation (Xenotransplantation)